IRIS
DI GIACOMO, ANNA MARIA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.571
EU - Europa 6.045
AS - Asia 4.501
SA - Sud America 1.104
AF - Africa 82
OC - Oceania 9
Totale 19.312
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.437
RU - Federazione Russa 1.844
SG - Singapore 1.844
CN - Cina 1.176
IT - Italia 1.176
IE - Irlanda 979
BR - Brasile 930
GB - Regno Unito 635
HK - Hong Kong 450
VN - Vietnam 393
DE - Germania 296
SE - Svezia 282
KR - Corea 240
FR - Francia 230
UA - Ucraina 182
IN - India 113
FI - Finlandia 98
NL - Olanda 97
ES - Italia 80
AR - Argentina 72
MX - Messico 57
CA - Canada 55
BD - Bangladesh 41
EC - Ecuador 40
AT - Austria 39
ZA - Sudafrica 39
PL - Polonia 28
ID - Indonesia 27
TR - Turchia 26
JP - Giappone 23
IQ - Iraq 22
IR - Iran 16
UZ - Uzbekistan 14
CO - Colombia 13
PK - Pakistan 13
SA - Arabia Saudita 13
PY - Paraguay 12
AZ - Azerbaigian 11
AE - Emirati Arabi Uniti 10
VE - Venezuela 10
BE - Belgio 9
CH - Svizzera 9
LT - Lituania 9
PE - Perù 9
AU - Australia 8
CL - Cile 8
EG - Egitto 8
MA - Marocco 8
KG - Kirghizistan 7
PH - Filippine 7
TN - Tunisia 7
AL - Albania 6
KZ - Kazakistan 6
NO - Norvegia 6
OM - Oman 6
BO - Bolivia 5
DK - Danimarca 5
DO - Repubblica Dominicana 5
DZ - Algeria 5
JO - Giordania 5
LB - Libano 5
BG - Bulgaria 4
BH - Bahrain 4
EE - Estonia 4
PA - Panama 4
PT - Portogallo 4
UY - Uruguay 4
AM - Armenia 3
BA - Bosnia-Erzegovina 3
BY - Bielorussia 3
CI - Costa d'Avorio 3
JM - Giamaica 3
KE - Kenya 3
LK - Sri Lanka 3
MD - Moldavia 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
AO - Angola 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
ET - Etiopia 2
GE - Georgia 2
GR - Grecia 2
HU - Ungheria 2
IL - Israele 2
KH - Cambogia 2
LA - Repubblica Popolare Democratica del Laos 2
MY - Malesia 2
NG - Nigeria 2
NP - Nepal 2
QA - Qatar 2
SV - El Salvador 2
TW - Taiwan 2
BN - Brunei Darussalam 1
CG - Congo 1
GA - Gabon 1
GD - Grenada 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
Totale 19.299
Salva come PNG Salva come JPEG
Città #
Dallas 1.524
Singapore 1.124
Dublin 974
Fairfield 817
Ashburn 557
Santa Clara 520
Moscow 518
Southend 453
Hong Kong 446
Woodbridge 399
Beijing 362
Seattle 348
Houston 314
Hefei 309
Cambridge 299
Wilmington 292
Siena 266
Seoul 232
Milan 175
Princeton 170
Jacksonville 157
Ann Arbor 134
Los Angeles 120
Chandler 117
Ho Chi Minh City 115
Florence 106
New York 103
Dong Ket 101
San Mateo 84
Shanghai 72
Rome 69
São Paulo 69
Dearborn 66
Amsterdam 58
The Dalles 58
Málaga 54
Helsinki 51
Redondo Beach 51
Bengaluru 50
San Diego 47
Buffalo 45
Hanoi 45
Nuremberg 45
Munich 42
London 36
Chicago 33
Rio de Janeiro 32
Stockholm 28
Brooklyn 27
San Francisco 27
Denver 26
Montreal 26
Nanjing 26
Lappeenranta 25
Lauterbourg 25
Vienna 24
Warsaw 23
Phoenix 22
Johannesburg 21
Portsmouth 21
Tokyo 21
Mexico City 20
Bologna 18
Guayaquil 18
Manchester 18
Belo Horizonte 17
Borgo San Lorenzo 17
Frankfurt am Main 17
Guangzhou 17
Orem 17
Perugia 17
Atlanta 16
Cascina 16
Fremont 16
Haiphong 16
Düsseldorf 15
Poplar 15
Turku 15
Chennai 14
Empoli 14
Brasília 13
Naples 13
Tashkent 13
Boardman 12
Porto Alegre 12
Redwood City 12
Salvador 12
Toronto 12
Ankara 11
Baku 11
Boston 11
Curitiba 11
Delhi 11
Sesto Fiorentino 11
Campinas 10
Guarulhos 10
Nanchang 10
Ninh Bình 10
Norwalk 10
Quito 10
Totale 12.939
Salva come PNG Salva come JPEG
Nome #
Neurological adverse events of ICI therapy: A ten-year comprehensive management from a multidisciplinary team 449
Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 325
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 313
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: Results of a phase II study 284
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 237
Ipilimumab in pretreated metastatic uveal melanoma patients: safety and clinical efficacy 235
Immunomodulatory properties of DNA hypomethylating agents: Selecting the optimal epigenetic partner for cancer immunotherapy 233
Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial 218
Circulating levels of PD-L1 in mesothelioma patients from the NIBIT-MESO-1 study: Correlation with survival 217
Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab 212
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. 208
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 201
Guadecitabine plus ipilimumab in unresectable melanoma: the NIBIT-M4 clinical trial 199
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 199
“Cancer Bio-Immunotherapy in Siena”: Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8–10, 2015 194
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 191
Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models 189
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 188
The italian experience on the feasibility and safety of ipilmumab therapy in pretracted metastatic melanoma patients 185
Back to simplicity: A four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients 185
Ipilmumab in the daily practice: feasibility, safety, efficacy and long term follow-up in heavily pretreated metastatic melanoma patients 183
Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/ mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study 183
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial 180
“Cancer Bio-Immunotherapy in Siena”: Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17–19, 2013 178
Ipilimumab in the common daily practice: feasibility, safety, efficacy and long-term follow-up in heavily pretreated metastatic melanoma patients 173
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 170
Epigenetic remodeling to improve the efficacy of immunotherapy in human glioblastoma: pre-clinical evidence for development of new immunotherapy approaches 169
Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients 169
Expression and regulation of B7-H3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: immunotherapeutic implications 168
Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial 167
Epigenetic immune remodeling of mesothelioma cells: A new strategy to improve the efficacy of immunotherapy 165
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 159
Immunotherapy targeting immune check-point(s) in brain metastases 158
A novel microRNA signature for the detection of melanoma by liquid biopsy 156
Predictors of responses to immune checkpoint blockade in advanced melanoma 156
A Phase II Study Combining Ipilimumab and Fotemustine in Patients With Metastatic Melanoma - the NIBIT-M1 Trial 155
Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab 153
The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications 151
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 151
Clinical Efficacy of the Anti-Cytotoxic T Lymphocyte Antigen-4 (CTLA-4) Monoclonal Antibody Ipilimumab in Pretreated Metastatic Uveal Melanoma Patients 150
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian network for tumor biotherapy (NIBIT)-M1 phase II study 150
Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial 148
Ipilimumab in the common daily practice: Feasibility, safety, and efficacy in heavily pretreated metastatic melanoma patients 147
Molecular pathways: At the crossroads of cancer epigenetics and immunotherapy 147
Rational Use of Monoclonal Antibodies as Therapeutic Treatment in an Oncologic Patient with Long COVID 145
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 144
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 143
Landscape of immune-related signatures induced by targeting of different epigenetic regulators in melanoma: implications for immunotherapy 143
A phase Ib study combining the second-generation DNA hypomethylating agent (DHA) guadecitabine (SGI-110) and ipilimumab in patients with metastatic melanoma: the NIBIT-M4 Study. 142
Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: Comparison with regulatory T cells and NY-ESO-1- or melan-A-specific T cells 141
Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond 141
A novel method for monitoring response to chemotherapy based on the detection of circulating cancer cells: A case report 141
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab 141
The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role? 138
Functional T cells targeting NY-ESO-1 or Melan-A are predictive for survival of patients with distant melanoma metastasis 138
Primary hepatic epithelioid hemangioendothelioma progressively responsive to interferon-alpha: is there room for novel anti-angiogenetic treatments? 137
Challenges in lung cancer therapy during the COVID-19 pandemic 133
Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases 132
Perspectives on the role of “-Omics” in predicting response to immunotherapy 129
Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial 125
Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications 125
Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients 125
Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study 125
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial 124
Ipilmumab in pretreated metastatic uveal melanoma patiens; safety and clinical efficacy 124
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 123
Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy 123
Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 122
Basal and one-month differed neutrophil, lymphocyte and platelet values and their ratios strongly predict the efficacy of checkpoint inhibitors immunotherapy in patients with advanced BRAF wild-type melanoma 120
Five-Year Outcomes With Nivolumab in Patients With Wild-Type BRAF Advanced Melanoma 120
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial 119
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria 119
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915) 119
Long-term follow-up of a papillary tumor of the pineal region: addendum to a case report 119
The Italian experience on the feasibility and safety of ipilimumab therapy in pretreated metastatic melanoma patients 118
Successful Targeting of CTLA-4 in a Melanoma Clinical Case: A Long-Term “One Stop Therapeutic Shop” 116
Correction to: Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery (Journal of Neuro-Oncology, (2024), 10.1007/s11060-024-04818-9) 113
Epigenetics meets immune checkpoints 111
Efficacy of ipilimumab plus nivolumab or ipilimumab plus fotemustine vs fotemustine in patients with melanoma metastatic to the brain: Primary analysis of the phase III NIBIT-M2 trial 110
Can epigenetics have a clinical impact in the treatment of melanoma? 108
Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: immunotherapeutic implications 108
Nivolumab plus ipilimumab in melanoma brain metastases 108
Effects of molecular heterogeneity on survival of patients with BRAFV600-mutated melanoma treated with vemurafenib with or without cobimetinib in the coBRIM study 107
Survival Outcomes in Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma Treated with Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial 107
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 106
From Co-Stimulation to Co-Inhibition: A Continuum of Immunotherapy Care Toward Long-Term Survival in Melanoma 105
Dietary compounds and cutaneous malignant melanoma: Recent advances from a biological perspective 104
Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix 104
Adjuvant nivolumab for stage III/IV melanoma: Evaluation of safety outcomes and association with recurrence-free survival 104
Safety and immunobiological activity of guadecitabine sequenced with ipilimumab in metastatic melanoma patients: The phase Ib NIBIT-M4 study 104
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238 102
Mutational concordance between primary and metastatic melanoma: A next-generation sequencing approach 102
Phase II multicenter trial of ipilimumab combined with fotemustine in patients with metastatic melanoma: The Italian Network for Tumor Biotherapy (NIBIT)-M1 trial 101
Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma 101
Epigenetic modulation of solid tumors as a novel approach for cancer immunotherapy 100
Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma 100
Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial 100
Predictive value of perilesional edema volume in melanoma brain metastasis response to stereotactic radiosurgery 99
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 99
The NIBIT-M1 trial: Activity of ipilimumab plus fotemustine in patients with melanoma and brain metastases 99
Totale 15.204
Salva come PNG Salva come JPEG
Categoria #
all - tutte 69.139
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.139
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.154 0 0 0 0 0 251 71 309 80 165 59 219
2021/2022989 43 87 91 20 18 65 34 42 74 137 123 255
2022/20231.326 106 86 212 113 58 235 42 67 92 56 219 40
2023/20241.661 63 62 152 61 49 393 551 62 44 24 38 162
2024/20254.287 121 148 319 234 459 278 139 175 479 323 455 1.157
2025/20267.363 790 1.430 1.420 1.350 2.273 100 0 0 0 0 0 0
Totale 19.938